0000874015-24-000078.txt : 20240118 0000874015-24-000078.hdr.sgml : 20240118 20240118174918 ACCESSION NUMBER: 0000874015-24-000078 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240116 FILED AS OF DATE: 20240118 DATE AS OF CHANGE: 20240118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Swayze Eric CENTRAL INDEX KEY: 0001791058 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 24543117 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT STREET 2: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330336973 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2024-01-16 0 0000874015 IONIS PHARMACEUTICALS INC IONS 0001791058 Swayze Eric 2855 GAZELLE COURT CARLSBAD CA 92010 0 1 0 0 EVP Research 0 Common Stock 2024-01-16 4 M 0 17069 0.0 A 49585 D Common Stock 2024-01-17 4 S 0 6296 50.417 D 43289 D Common Stock 2024-01-16 4 M 0 21 0.0 A 94 I by Son Common Stock 2024-01-17 4 S 0 9 50.417 D 85 I by Son Restricted Stock Unit 0.0 2024-01-16 4 M 0 17069 0.0 D Common Stock 17069 46728 D Restricted Stock Unit 0.0 2024-01-16 4 M 0 21 0.0 D Common Stock 21 551 I by Son Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.43, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4. Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. By: Patrick R. O'Neil, attorney-in-fact For: Eric Swayze 2024-01-18